
Education and Training
- Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2012 - 2015
- Internal Medicine Residency, Medicine, Duke University School of Medicine, 2009 - 2012
- M.H.S., Duke University School of Medicine, 2019
- M.D., Harvard Medical School, 2009
Grants
- NeoImmune NMTNT110
- A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (Mirati 516-003)
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
- A Salvage Trial of AR Inhibition with ADT and Apalutamide with Docetaxel followed by Radiation Therapy in Men with PSA Recurrent Prostate Cancer after Radical Prostatectomy (¿STARTAR¿)
- An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
- The impact of genetic diversity among Akkermansia strains on the effectivenes of immune checkpoint inhibitors in cancer immunotherapies
- A first in human study of repeat dosing with REGN2810 a fully human antibody to programmed death - 1 (PD-1) as single therapy and in combination with selected
- Phase II study of AGS-16C3F vs Axitinib in Metastatic Renal Cell Carcinoma
- Immune correlates of immunotherapy responses in renal cell carcinoma
- Predicting patient-specific responses to personalize androgen deprivation therapy for prostate cancer
- A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN (VBIR) FOR PROSTATE CANCER (PF-06753512)
- Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer
- Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
- Defining the Relevant Immune Checkpoints Expressed on Metastatic Prostate Cancer Circulating Tumor Cells